{
    "nct_id": "NCT05091567",
    "official_title": "A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab",
    "inclusion_criteria": "Inclusion Criteria for the Induction Phase:\n\n* ECOG PS of 0 or 1\n* No prior systemic therapy for ES-SCLC\n* Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC\n* Histologically or cytologically confirmed ES-SCLC\n* Adequate hematologic and end-organ function to receive 4 cycles of induction treatment with carboplatin, etoposide and atezolizumab\n* Measurable disease, as defined by RECIST v1.1\n* Negative HIV test and no evidence of active Hepatitis B or Hepatitis C at screening\n\nExclusion Criteria for the Induction Phase:\n\n* Presence or history of CNS metastases\n* Active or history of autoimmune disease or deficiency\n* History of malignancies other than SCLC within 5 years prior to enrollment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or lurbinectedin or trabectedin\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Treatment with investigational therapy within 28 days prior to enrollment\n\nInclusion Criteria for the Maintenance Phase:\n\n* ECOG PS of 0 or 1\n* Ongoing response or stable disease per RECIST 1.1 after 4 cycles of induction therapy\n* Toxicities attributed to prior induction anti-cancer therapy or PCI resolved to Grade <=1\n* Adequate hematologic and end-organ function\n\nExclusion Criteria for the Maintenance Phase:\n\n* Presence or history of CNS metastases\n* Receiving consolidative chest radiation\n* Severe infection within 2 weeks prior to randomization into the maintenance\n* Treatment with therapeutic oral or IV antibiotics at the time of randomization\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}